University Of Washington
University Of Washington is a leading research university with three campuses, a world-class academic medical center, and extensive continuing education programs. The students, faculty, and researchers at UW are driven to turn ideas into actions and impact.
Through prime federal contract awards, University Of Washington has provided a range of goods and services, including sole source affiliate physician services in dermatology and ophthalmology to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 with no set-aside designation; research services to the Defense Advanced Research Projects Agency to continue work on the Robotic Autonomy in Complex Environments with Resiliency program with no set-aside; and research services to the National Aeronautics and Space Administration Shared Services Center to analyze critical data from comet Wild 2 silicates and advance understanding of comet formation environments with no set-aside designation. As a subcontractor, University Of Washington has contributed to research objectives on topics ranging from program transformation and verification techniques to support assured micro patches for mission-critical software under prime contractor University of Michigan; to structural characterization of SARS-CoV-2 variants under prime contractor Seattle Children's Hospital.
Through prime federal grant awards, University Of Washington has received funding to investigate the role of the endoplasmic reticulum unfolded protein response in tauopathy from the National Institute on Aging; to study associations between influenza vaccination during pregnancy and outcomes related to maternal influenza disease, infant anthropometry, and cost-effectiveness in rural Nepal from the National Institute of Allergy and Infectious Diseases; and to develop an optical imaging/intravascular ultrasound-guided micropuncture system for transjugular intrahepatic portosystemic shunt from the National Institute of Biomedical Imaging and Bioengineering. As a subrecipient under federal grants, University Of Washington has contributed expertise and resources in areas such as non-invasive MRI imaging in a study of glymphatic function in individuals with TBI under prime grantee Seattle Institute for Biomedical and Clinical Research; and research on ocean dynamics governing melt at glaciers using Lagrangian floats under prime grantee University of Minnesota.
University Of Washington holds a single award indefinite delivery contract from the National Institutes of Health National Heart, Lung and Blood Institute with a potential value of $500 million to provide Centralized Omics Resource DNA Methylation services over a 10-year period from September 2023 through September 2033, with no parent contract vehicles indicated. A $2.99 million firm fixed price delivery order was issued against this IDC to University Of Washington for DNA Methylation services from September 2023 through September 2024.
HD1WMN6945W6 611310
Not listed University of Washington Tower Building T, 4333 Brooklyn Ave NE, Seattle, WA 98105, USA
11/6/01 7/8/25 The Broad Institute, Inc.
The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, is a non-profit biomedical and genomic research organization that partners with universities, medical centers, and companies to advance understanding of human disease. Its mission is to lay the scientific foundation for the next generation of disease cures by carrying out disease area-based, cross-disciplinary research programs. Through federal contract awards from agencies like the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Department of Defense (DoD), and National Science Foundation (NSF), The Broad Institute provides an array of scientific services. These include genomic sequencing, data analysis, genome engineering, advanced computational biology, scientific software development, and translational research. The Broad collaborates with private companies, academic institutions, non-profits, and government entities as either the prime contractor or subcontractor, leveraging complementary expertise.
The Broad Institute has received numerous prime and sub federal contract awards to provide specialized scientific services. For the NIH, The Broad has conducted high-throughput whole exome sequencing on patient samples, performed genomic analyses to detect mutations and clonal architecture in cancer studies, and provided proteomics services using mass spectrometry. Under contracts with the CDC, The Broad has carried out genomic sequencing and analysis of infectious disease samples. For the DoD, The Broad has investigated mechanisms of drug resistance in cancers and developed novel antimalarial compounds. Many of these contract awards have no set-aside designation, reflecting The Broad's status as a large non-profit research organization. The Broad frequently partners with academic medical centers like Dana-Farber Cancer Institute and Massachusetts General Hospital on contract work.
The Broad Institute receives substantial grant funding from NIH institutes and centers such as the National Cancer Institute, National Institute of Mental Health, National Human Genome Research Institute, and Office of the Director. Research supported by these grants spans a wide range of areas like cancer, neuroscience, infectious disease, genomics, data science, and genome editing technology development. Broad researchers apply techniques like single-cell sequencing, spatial transcriptomics, proteomics, and metabolomics to investigate disease biology and identify therapeutic targets. The Broad frequently collaborates with partners from academia, healthcare, and industry on grant-funded projects. For example, The Broad partners with multiple universities on large-scale projects to map brain cell types and study psychiatric disorders. The institute also receives grant funding from other agencies like the DoD to advance biomedical research with potential defense applications.
The Broad Institute holds an indefinite delivery contract from the National Heart, Lung and Blood Institute to support the Trans-Omics for Precision Medicine initiative through genomics data generation, analysis, and management services. This single-award IDV has a $500 million ceiling over a 10-year period. The Broad was also awarded a multiple award IDIQ under the Brain Initiative Cell Atlas Network sequencing core program to provide large-scale DNA sequencing and related capabilities across tissue types to map cell atlases of the brain. This IDV has a $149 million ceiling shared among awardees over a 7-year period. Both of these IDCs involve task orders for work performed in Cambridge, MA by the Broad's Genomics Platform. These vehicles enable The Broad to efficiently provide genomic services to support major NIH research initiatives.
H5G9NWEFHXN4 541714
Not listed 415 Main St, Cambridge, MA 02142, USA
2/17/09 7/3/25 New York Genome Center, Inc.
New York Genome Center, Inc., doing business as Nygc, is a nonprofit academic research institution advancing genomic research for neurodegenerative, neuropsychiatric, and cancer diseases through collaboration and innovation. It provides a range of genomic sequencing, analysis, and computational services to federal agencies through contract and grant awards. Nygc has delivered next-generation sequencing, whole genome sequencing, RNA sequencing, single-cell genomic analysis, and other genomic characterization services to the Department of Veterans Affairs, National Institutes of Health, National Cancer Institute, National Heart, Lung and Blood Institute, National Institute on Drug Abuse, and other agencies and institutes. As both a prime contractor and subcontractor, Nygc often works with academic partners like medical schools and research universities to advance genomics research.
Through federal contract awards, Nygc has provided specialized genomic sequencing and analysis services. For the VA, Nygc has performed next-generation sequencing to support ongoing research studies. With NIH institutes like NCI, NHLBI, and NIDA, Nygc has delivered RNA sequencing, whole genome sequencing, and other genomic characterization services to support initiatives like the Trans-Omics for Precision Medicine program and the BRAIN Initiative Cell Atlas Network. Many of Nygc's contract awards do not have set-aside designations, reflecting the specialized nature of its genomic services. As a subcontractor, Nygc has supported prime contractors like Weill Cornell Medicine in delivering sequencing and bioinformatics services for federal cancer genomics programs.
Nygc's federal grant work has focused on innovative genomic research involving techniques like CRISPR screens, single-cell multiomics, spatial transcriptomics, and integrating epigenomic data. Key research areas have included mapping genetic variants associated with neuropsychiatric disorders, characterizing cellular heterogeneity in diseases, multi-omics of aging biology, and cancer genomics. Nygc has received numerous project grants and cooperative agreements from NIH institutes like NIMH, NHGRI, NCI, and NIGMS. Many of these awards have involved collaborations with academic partners in fields like systems biology, neuroscience, and oncology. As a subrecipient, Nygc has supported prime grantees like Columbia University and Mount Sinai in areas such as Alzheimer's disease research and psychiatric genomics.
Nygc holds several notable indefinite delivery contracts and master IDIQs. It has a $500 million Trans-Omics for Precision Medicine IDIQ with NHLBI to provide centralized omics data analysis and management for large health datasets supporting precision medicine research. Nygc also holds a $149 million BRAIN Initiative Cell Atlas Network Sequencing Core IDIQ issued by NIDA for sequencing services to map cell types in the brain. Under this vehicle, Nygc has received over $110 million in delivery orders to date from NIDA. Other IDVs support cancer genomic characterization for NCI and research sequencing for the VA. These vehicles allow Nygc to efficiently deliver its specialized genomic services to support major federal biomedical research initiatives.
WKPTJDWG2C68 541714
Not listed 101 6th Ave #7, New York, NY 10013, USA
7/17/12 11/21/25